Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001999371-25-017370
Filing Date
2025-11-10
Accepted
2025-11-10 16:30:58
Documents
88
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT tnxp-10q_093025.htm   iXBRL 10-Q 1326770
2 CERTIFICATION OF CHIEF EXECUTIVE OFFICER ex31-01.htm EX-31.1 15407
3 CERTIFICATION OF CHIEF FINANCIAL OFFICER ex31-02.htm EX-31.2 15822
4 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER ex32-01.htm EX-32.1 9367
  Complete submission text file 0001999371-25-017370.txt   7613187

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE tnxp-20250930.xsd EX-101.SCH 63237
6 XBRL CALCULATION FILE tnxp-20250930_cal.xml EX-101.CAL 80013
7 XBRL DEFINITION FILE tnxp-20250930_def.xml EX-101.DEF 228349
8 XBRL LABEL FILE tnxp-20250930_lab.xml EX-101.LAB 509565
9 XBRL PRESENTATION FILE tnxp-20250930_pre.xml EX-101.PRE 395901
91 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-10q_093025_htm.xml XML 1219955
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36019 | Film No.: 251466729
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)